Injective is rising today: what traders are watching (January 6)

Traders Union
All News
Crypto
Injective Surges 11.24% to $5.65 Today

Highlights

Injective removed over 6.8 million INJ from circulation in early 2026 via a major community buyback and token burn as part of supply management.
Daily active users on Injective reached record levels, driven by low fees and enhanced cross-chain functionality.
Upcoming infrastructure upgrades include the MultiVM mainnet with EVM and SVM compatibility, alongside institutional interest in a proposed staked INJ ETF and new treasury initiatives.

Supply reduction and user growth as buyback, burn drive sentiment

Injective completed a major community buyback and token burn in early 2026, removing over 6.8 million INJ from circulation as part of a continuing supply management strategy. The project has also seen daily active users reach record levels, supported by low fees and cross-chain functionality. Infrastructure upgrades are planned, such as the MultiVM mainnet with EVM and SVM compatibility, while institutional interest is growing with a proposed staked INJ ETF and new treasury initiatives.

Anton Kharitonov, expert at Traders Union, sees clear technical divergence across timeframes. He notes that despite a sharp short-term rally, the price remains well below the MA-200 and is at risk if Ichimoku support at $4.98 fails. Sentiment from recent buybacks and ETF rumors is strong, but he questions sustainability given the overbought readings and persistent long-term bearish signals. Kharitonov warns that high volatility may trap buyers at elevated levels. "Unless INJ reclaims $6.00 with conviction, downside risks outweigh near-term enthusiasm in my view."

Viktoras Karapetjanc, expert at Traders Union, believes the bullish structure remains intact for INJ. He highlights the successful token burn, rapid user growth, and upcoming MultiVM mainnet as key drivers of expanding institutional and retail engagement. The proposed ETF and treasury initiatives signal strategic maturity. Karapetjanc suggests multiple opportunities for further growth exist as technical and fundamental factors align. "Current market dynamics set the stage for INJ to unlock higher levels as adoption and innovation continue."

Jainam Mehta, market strategist, points out mixed momentum signals and a gap up that could present tactical trade setups. He stresses that the band between $5.54 and $5.58 may cap near-term gains, but a break above $6.00 could trigger a fresh leg higher. Divergence across timeframes creates potential for both breakout and mean-reversion strategies. "A contrarian entry may emerge if momentum fades and price retests structural supports."

Mixed momentum signals amid strong intraday surge and overbought risks

Momentum readings are mixed: the daily MACD remains in strong sell territory, contrasting with firm intraday momentum suggested by the ADX (28.38, buy in lower time frames) and a robust 11.24% price surge. Oscillators such as Stoch RSI and CCI flag overbought conditions, while BBP (0.63) suggests buyers currently dominate intraday trade. The RSI D1 supports further upside, but these overbought signals and the neutral Awesome Oscillator highlight ongoing divergence. The session opened with a clear gap up from $5.08 to $5.39 and continued higher, with the current price holding near today's range top ($5.56), suggesting high volatility and sustained buying pressure after the open.

Previously it was reported that Injective displayed short-term bullish momentum above its 20- and 50-day moving averages, but remained well below the 200-day, with mixed technical indicators — RSI supportive near 58, MACD and ADX showing underlying weakness, and both Stoch RSI and CCI signaling overbought conditions. Immediate technical levels were in focus as dynamic support at $4.98 held, while resistance near $5.50 capped gains and analysts expected sideways or downward moves are more probable amid pronounced intraday volatility.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.